Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post by Ilana Schlam, Breast medical oncologist at Dana-Farber Cancer Institute, adding:
“Among pts with ER+/HER2+ MBC, maintenance HP (control arm) had a PFS of: -29.1 mo in PATINA -16.3 mo in HER2CLIMB-05 The difference? In PATINA all pts also received ET (only 45% in H2C-05). Reminder that, besides fancy new drugs, ET can REALLY make a difference in this disease!”
Quoting Ilana Schlam‘s post:
“Nice table to put this rapidly evolving field in perspective.”
Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Paolo Tarantino, adding:
“New standard of care for ER negative; HER-2 positive maintenance with HP. I hope the indication comes regardless of first-line induction strategy.”